Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

Thomas P. AhernDepartment of Surgery, University of Vermont College of Medicine, Burlington, Vermont, USA; Correspondence[email protected]

Deirdre P. Cronin-FentonDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;

Timothy L. LashDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; ;Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA;

Henrik Toft SørensenDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;

Anne Gulbech OrdingDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;

Stephen J. Hamilton-DutoitInstitute of Pathology, Aarhus University Hospital, Aarhus, Denmark;

Ylva HellbergInstitute of Pathology, Aarhus University Hospital, Aarhus, Denmark; ;Department of Pathology, Hvidovre Hospital, Hvidovre Municipality, Denmark

show all

Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date